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Abstract
Aims/hypothesis Vascular inflammation and endothelial dys-
function are thought to contribute to arterial stiffening and
hypertension. This study aims to test this hypothesis with lon-
gitudinal data in the context of type 1 diabetes.
Methods We investigated, in an inception cohort of 277 indi-
viduals with type 1 diabetes, the course, tracking and temporal
inter-relationships of BP, specifically pulse pressure (a marker
of arterial stiffening) and hypertension, and the following bio-
markers of systemic and vascular inflammation/endothelial
dysfunction: C-reactive protein (CRP), soluble intracellular
adhesion molecule-1 (sICAM-1), soluble vascular cellular ad-
hesion molecule-1 (sVCAM-1) and soluble E-selectin
(sE-selectin). These biomarkers and other risk factors were
measured at baseline and repeatedly up to 20 years after the
onset of type 1 diabetes. Data were analysed with generalised
estimating equations including adjustments for age, sex,
smoking status, BMI, HbA1c, serum creatinine, total choles-
terol, urinary AER, insulin treatment dose and mean arterial
pressure.
Results Increases were noted in all biomarkers except
sE-selectin, which decreased over time. Levels differed from
baseline at 2–4 years and preceded the increase in pulse pres-
sure, which occurred at 8–10 years after the onset of type 1
diabetes. Higher levels of sICAM-1 and sVCAM-1, but not
CRP or sE-selectin, at baseline and throughout the 20 year
follow-up, were significantly associated with higher (changes
in) pulse pressure at subsequent time points. Higher levels of
sVCAM-1 at baseline and during follow-up were also signif-
icantly associated with the prevalence (OR 3.60 [95%CI 1.36,
9.53] and OR 2.28 [1.03, 5.25], respectively) and incidence
(OR 2.89 [1.08, 7.75] and OR 3.06 [1.01, 9.26], respectively)
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of hypertension. We also investigated the longitudinal associ-
ations between BP or hypertension as determinants of subse-
quent (changes in) levels of CRP, sICAM-1, sVCAM-1 and
sE-selectin, but did not find evidence to support a reverse
causality hypothesis.
Conclusions/interpretation These findings support the in-
volvement of vascular endothelial dysfunction and inflamma-
tion in the development of premature arterial stiffening and
hypertension in type 1 diabetes.
Keywords Arterial stiffness .CRP .Endothelial dysfunction .
Hypertension . Inflammation . Longitudinal study . Pulse
pressure .sE-selectin .sICAM-1 .sVCAM-1 .Type1diabetes
Abbreviations
CAM Cellular adhesion molecule
CRP C-reactive protein
CVD Cardiovascular disease
DBP Diastolic BP
GEE Generalised estimating equation
MAP Mean arterial pressure
SBP Systolic BP
sE-selectin Soluble E-selectin
sICAM-1 Soluble intracellular adhesion molecule-1
sVCAM-1 Soluble vascular cellular adhesion molecule-1
Introduction
Individuals with type 1 diabetes are characterised by accelerat-
ed arterial ageing [1, 2], a mechanism that increases the risk for
cardiovascular disease (CVD) [2–4]. This has been illustrated
by a steeper positive association between age and pulse pres-
sure, amarker of arterial stiffness [5, 6], in individuals with type
1 diabetes than in their peers without the disease [1]. This is
also supported by many studies demonstrating greater arterial
stiffness in diabetes, as ascertained bymeasures of arterial pulse
wave velocity or local estimates such as distensibility coeffi-
cients of the carotid and others arteries [3]. Importantly, in
individuals with type 1 diabetes, higher pulse pressure (pulsa-
tile load) has been associated with incident CVD independently
of mean arterial pressure (MAP; steady load) [2].
The pathobiological mechanisms underlying the increases
in pulse pressure in individuals with diabetes are, however,
not clear. Diabetes is characterised by systemic and vascular
inflammation and endothelial dysfunction [7–9], mechanisms
that may link type 1 diabetes to increased pulse pressure [3].
Indeed, in recent years, inflammation and endothelial dys-
function, as expressed by levels of C-reactive protein (CRP)
and cellular adhesion molecules (CAMs), have been proposed
as putative determinants of arterial stiffness/pulse pressure and
hypertension [10–12]. Epidemiological evidence to support
this hypothesis remains weak, however, mainly due to limita-
tions in study design. In addition, this has never been exam-
ined in the context of type 1 diabetes.
We have therefore investigated the longitudinal course of
BP and markers of systemic and vascular inflammation and
endothelial dysfunction (CRP, soluble intracellular adhesion
molecule-1 [sICAM-1], soluble vascular cellular adhesion
molecule-1 [sVCAM-1], and soluble E-selectin [sE-selectin])
and their temporal inter-relationships, in a cohort of individ-
uals with type 1 diabetes who were followed over 20 years,
since the onset of disease.
Methods
Study population and design
All individuals newly diagnosed with type 1 diabetes, consec-
utively admitted to the Steno Diabetes Centre between 1
September 1979 and 31 August 1984, were included in an
inception cohort (n = 286), which has been described in detail
previously [13, 14].
All participants attended the outpatient clinic every 3–
4 months as part of their routine evaluation throughout a total
follow-up period of ~20 years (median 18 years; range
1.1–21.5 years) up until 31 December 2000. These routine
evaluations included measures of BP, HbA1c, BMI, serum
cholesterol and creatinine, and urinary AER as described in
detail elsewhere [13–15]. Throughout the years, participants
were treated by diabetologists and nurses according to con-
temporaneous principles and guidelines [14, 16]. No specific
intervention was carried out.
In line with previous reports in this cohort, we excluded
from the analyses seven individuals with serious mental ill-
ness and two with microalbuminuria at onset of disease
[13–15]. Therefore, the present study reports on analyses con-
ducted using all clinical data obtained from 277 individuals
over the course of follow-up. Of these individuals, 29 died and
19 moved out of care at the Steno Diabetes Centre at different
follow-up times. The exact number of individuals analysed
per time interval and the total number of observations made
are summarised in electronic supplementary material (ESM)
Table 1.
The local ethics committee (Copenhagen County,
Denmark) approved the study and all individuals gave written
informed consent for their participation in the study.
Biomarkers of low-grade inflammation and endothelial
dysfunction
All biomarkers were measured recently in stored blood sam-
ples that had been collected throughout the whole follow-up
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period. For each individual, samples spaced approximately
2 years apart were selected for these assessments. CRP was
measured with a high-sensitivity in-house ELISAwith rabbit
anti-CRP (Dako, Copenhagen, Denmark) as a catching and
tagging antibody as described previously, with intra- and
inter-assay CVof 3.8% and 4.7%, respectively [8]. sVCAM-
1, sICAM-1 and sE-selectin were measured in duplicate using
commercially available ELISA kits (Diaclone, Besançon,
France); the intra- and inter-assay CV was, respectively,
1.8% and 4.2% for sICAM-1, 1.1% and 3.1% for sVCAM-
1, and 4.2% and 8.5% for sE-selectin.
BP, hypertension and antihypertensive treatment
BP was measured at least once yearly with a standard sphyg-
momanometer and an appropriate cuff size. The measure-
ments were performed, with participants in the sitting position
after 10min of rest, by attending physicians and trained nurses
who were instructed to obtain twomeasurements. The average
of these was reported in the participants’ files and used in the
analyses. Because the recorded BP of patients receiving anti-
hypertensive treatment is lower than the inherent untreated
level, without appropriate correction, one is likely to obtain
underestimates of the effects of potential determinants of BP
[17]. Therefore, the recorded systolic BP (SBP) and diastolic
BP (DBP) values under treatment were increased according to
the algorithm proposed by Wu et al [18]. This method of
adjustment is widely used in life-course analyses of BP [19]
and has been shown to be effective at reducing the potentially
distorting influence of antihypertensive treatment in studies
examining its determinants [17]. Pulse pressure was then cal-
culated as SBP – DBP and MAP as [(2 × DBP) + SBP] / 3.
In this cohort, criteria for the diagnosis of hypertension
(triggering initiation of antihypertensive treatment) changed
over the follow-up period: up until 1995 the WHO criteri-
on (≥160/95 mmHg) was used, and the ADA criterion
(≥140/90 mmHg) thereafter [20]. Because ~80% of all
participants’ time in the study occurred while the WHO
criteria were in use, their hypertension status thus mostly
reflects these criteria. Throughout the years, an increasing
range of antihypertensive drugs became available.
Accordingly, before 1991, selective β-blockers, diuretics
and vasodilators were used in this cohort. After 1991, β-
blockers, diuretics, calcium channel blockers (mainly
dihydropyridines) and ACE inhibitors (the predominant
type of drug prescribed) were used. In addition, from
1994 onwards ACE inhibitors started to be used for the
prevention of diabetic nephropathy [21] and, since then,
patients who progressed to persistent microalbuminuria
were treated with these drugs, regardless of their hyperten-
sive status. Angiotensin II receptor blockers were used if
ACE inhibitors were not tolerated (in seven patients only).
Data organisation and statistical analyses
All analyses were carried out using STATA software package,
version 14.0 (StataCorp, College Station, TX, USA).
All clinical data obtained from 6 months after the onset of
diabetes (i.e. after initial stabilisation of blood glucose levels)
up to 21.5 years thereafter (the maximum follow-up duration)
were aggregated within 2 year time intervals. The number of
readings available on the participants’ records varied per var-
iable within each 2 year time interval (e.g. only one for the key
determinants [biomarkers], only two [for BP] or more than
two [body weight, HbA1c]); whenever more than one reading
was available, median values were calculated when aggregat-
ing the data.
Missing data Over the course of the follow-up period, differ-
ent time-dependent variables were missing; sometimes this
was transitory (if the variable was not measured or was mea-
sured but not noted in a participant’s file at intermittent time
points) and sometimes data became permanently missing after
a participant dropped out or died. We used the two-fold Fully
Conditional Specification algorithm method for multiple im-
putation of longitudinal records of routinely collected clinical
variables to impute missing data [22]. In brief, missing values
at a given time point (t) were imputed conditional on all in-
formation available at the same and immediately adjacent t.
We used a window of t ± 4 years and specified study entry and
exit times for each participant so that imputations were not
done outside these (i.e. after maximal follow-up date or
death), which would assume an immortal cohort. Instead, in
our study the target of inference was the mortal cohort (where
only the surviving participants were included at each wave),
hence the method chosen to impute the missing data [23].
Twenty imputed datasets were generated and all results report-
ed are those from pooled analyses across all datasets.
Longitudinal analyses All data were analysed by using linear
(for continuous outcomes) or logistic (for dichotomous out-
comes) generalised estimating equations (GEEs) to account,
when appropriate, for the correlation and the unequal number
of repeated observations taken in the same individuals over
time [24]. Dichotomous outcomes were hypertension preva-
lence (proportion with hypertension at a given t irrespective
of prior status) or incidence (proportion with a first diagnosis
of hypertension at a given t among all those free of hyperten-
sion up to that t). All GEE models were fit using an exchange-
able correlation structure, except for the models with incident
hypertension as the main outcome where an independent cor-
relation structure was used instead (analogous to a discrete time
hazard model).
To investigate the mean yearly rates of change in BP and
biomarkers, and the prevalence of hypertension at each t, we
first examined the relationship of these variables with time.
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The exact (geometric) means and respective 95% CIs of bio-
markers and BP and the prevalence of hypertension (in %) at
each t were obtained by modelling time as a categorical vari-
able (displayed graphically).
To analyse tracking of biomarkers and BP over the 20 year
period, we used a model in which the initial value of each of
these variables (i.e. at 0–2 years [t0–2]) was regressed on the
entire subsequent levels of the same variable during follow-up
(i.e. t2–4 to t18–20, tracking GEEmodel; see ESM Fig. 1a) [25].
Time-specific z scores of each variable were used in these
analyses so that the tracking coefficients obtained could be
interpreted as longitudinal correlation coefficients that range
between 0 (no correlation) and 1 (perfect correlation).
We then used three complementary analytical models to
examine the associations between biomarkers (main deter-
minants) and BP (main outcomes), all modelling the levels
of main determinants at time intervals prior to those of the
outcomes, to minimise the possibility of overlap of the de-
terminants and outcomes assessment times and enable infer-
ences of causality. First, we examined the extent to which
individual differences in biomarkers at baseline predicted
individual differences in BP and the prevalence and inci-
dence of hypertension over the entire follow-up period
(baseline GEE model; ESM Fig. 1b). Second, we considered
the time-varying nature of the determinants and the out-
comes and examined their longitudinal associations with
the use of a time-lagged GEE model (ESM Fig. 1c). With
this model, we addressed the question of whether inter-
individual differences in biomarkers at one t predicted sub-
sequent inter-individual differences in BP (i.e. at t + 2 years).
Finally, we investigated the extent to which inter-individual
differences in main determinants at t predicted subsequent
intra-individual changes in outcomes (i.e. between t + 2 and
t + 4) using a time-lagged (changes) GEE model (ESM Fig.
1d). Time-lagged and changes models, as described above,
were also used to examine the possibility of reverse causal-
ity, by considering BP or hypertension as determinants and
biomarkers as outcomes.
All analytical models were first adjusted for time, and age
at onset of diabetes, sex and smoking history (as time-
independent covariates) and, second, for HbA1c, BMI, total
cholesterol, urinary AER, serum creatinine and daily insulin
dose (as time-dependent covariates). In analyses with pulse
pressure as main outcome, we additionally adjusted for
MAP to ascertain if any observed associations could be attrib-
uted to arterial stiffness independently of peripheral resistance
[5]. Biomarkers were loge transformed because of their right-
skewed distribution. In analyses with these variables as main
determinants of BP, longitudinal linear regression coefficients
or ORs are therefore expressed as differences in BP (in
mmHg) or odds of hypertension per doubling of each bio-
marker. In analyses of BP variables as main determinants of
biomarkers (reverse causality models), longitudinal linear
regression coefficients are expressed as per cent difference in
biomarker per 10 mmHg increase in BP variable.
Results
Characteristics of the study participants at baseline are shown
in Table 1.
Longitudinal development of BP, hypertension
and biomarkers
BP increased significantly over the 20 year longitudinal period
(Fig. 1a). When a linear relationship with time was assumed,
and after adjustments for all time-independent and time-
dependent covariates, the average increase per year was
Table 1 Baseline characteristics of the study population
Characteristic Measurement
Women, % 41.2
Age, years 27.4 ± 13.8
Smoking historya
Never smoked, % 33.2
Ex smoker, % 21.3
Current smoker, % 45.5
Height, cm 171.6 ± 12.5
Weight, kg 64.1 ± 13.2
BMI, kg/m2 21.5 ± 2.6
HbA1c, % 8.1 ± 1.5
HbA1c, mmol/mol 65.0 ± 7.1
Insulin use, U/day 27.9 ± 11.7
Total cholesterol, mmol/l 5.14 ± 1.92
Serum creatinine, μmol/l 78.5 ± 16.7
Estimated GFRb, ml min−1 (1.73 m)−2 104.8 ± 23.1
Urinary AER, mg/24 h 9.8 (8.6, 11.1)
BP, mmHg
SBP 121.8 ± 18.6
DBP 74.8 ± 11.3
MAP 90.4 ± 12.6
Pulse pressure 47.0 ± 13.7
Hypertension, % 1.1
CRP, nmol/l 5.71 (4.86, 6.76)
sICAM-1, ng/ml 639 (615, 663)
sVCAM-1, ng/ml 1189 (1148, 1230)
sE-selectin, ng/ml 142 (132, 152)
Data are shown as %, means ± SD or geometric means (95%CI); n = 277
a Includes 12 individuals who have smoked only during a portion of the
follow-up
b Estimated according to the Chronic Kidney Disease Epidemiology
Collaboration equation
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1.21 mmHg (95% CI 1.02, 1.40) for SBP, 0.53 mmHg (0.43,
0.64) for DBP, 0.76 mmHg (0.63, 0.89) for MAP and
0.67 mmHg (0.53, 0.80) for pulse pressure (all p < 0.001).
The estimated prevalence of hypertension over the 20 year
follow-up is shown in Fig. 1b.
Markers of low-grade inflammation and endothelial dys-
function also changed significantly over time (Fig. 2a–d).
When a linear relationship with time was assumed, and after
adjustments for all covariates, there was a yearly increase of
1.7% (95% CI 0.2, 3.2) for CRP, 0.3% (0.1, 0.7) for sICAM-1
and 0.6% (0.2, 0.9) for sVCAM-1, whereas sE-selectin de-
creased by 0.9% (−1.4, −0.3) each year (all p < 0.05).
The increases in levels of biomarkers (except sE-selectin)
were observed early; levels already differed from baseline at
2–4 years after onset of disease and preceded the increases in
BP, which differed significantly from baseline at 8–10 years
after the onset of type 1 diabetes (Figs 1 and 2).
Tracking of BP and biomarkers
After adjustments for all time-independent and time-
dependent covariates, tracking coefficients of BP over the
20 years of follow-up ranged between 0.26 (pulse pressure)
and 0.36 (SBP and MAP) (Table 2). Except for CRP, tracking
coefficients for the biomarkers were considerably higher (all
≥0.58) (Table 2).
Longitudinal associations between biomarkers and pulse
pressure
After adjustments for age, sex and smoking (model 1) and for
the baseline levels of the other risk factors (model 2), higher
levels of sICAM-1 and sVCAM-1, but not of CRP or
sE-selectin, at baseline were significantly associated with
higher pulse pressure during the 20 years of follow-up (base-
line GEE model, Table 3). However, the association with
sVCAM-1 was attenuated and no longer significant after ad-
ditional adjustment for MAP (model 3).
In analyses considering the time-varying nature of not only
the outcomes (BP) but also the main exposures (biomarkers),
and after adjustments for age, sex and smoking status (model
1), CRP, sICAM-1 and sVCAM-1 were all significantly asso-
ciated with higher subsequent pulse pressure: 0.75 mmHg
(95% CI 0.18, 1.33), 3.93 mmHg (0.62, 7.25) and
5.13 mmHg (1.86, 8.40) per doubling in each biomarker, re-
spectively (time-lagged GEEmodel, Table 3). The adjustments
for the time-varying covariates attenuated the association be-
tween CRP and pulse pressure markedly, to 0.27 mmHg
(−0.32, 0.86), but did not importantly affect the associations
between sICAM-1 or sVCAM-1 and pulse pressure (models
1 vs 2). After further adjustments for MAP (model 3), both
sICAM-1 and sVCAM-1 remained significantly associated
with subsequent pulse pressure, although the strength of the
association with sVCAM-1 was attenuated more markedly:
3.15 mmHg (0.44, 5.87) and 3.23 mmHg (0.49, 5.98) per dou-
bling in sICAM-1 and sVCAM-1, respectively.
After adjustments for all covariates considered, including
changes in MAP (model 3), higher levels of sICAM-1 and
sVCAM-1, but not of CRP or sE-selectin, also predicted sub-
sequent changes in pulse pressure: 2.47mmHg (0.16, 4.78) and
2.54 mmHg (0.12, 4.96) per doubling in sICAM-1 and
sVCAM-1, respectively (time-lagged changes GEE model,
Table 3).
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Fig. 1 (a) Twenty-year time course of SBP (triangles), DBP (inverted
triangles), MAP (circles) and pulse pressure (squares). Data show means
and 95% CIs, adjusted for time-independent and time-dependent covari-
ates; dashed lines represent unadjusted levels of BP. BP levels at disease
onset (indicated by arrow) are shown for descriptive purposes only. (b)
Estimated prevalence of hypertension at each time point. *p < 0.05,
**p < 0.01 and ***p < 0.001 vs 0–2 years (baseline)
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The significant associations between CAMs and pulse
pressure described above derived from distinct patterns of
association; specifically, sVCAM-1 was positively associated
with both SBP and DBP but more strongly so with SBP,
whereas sICAM-1 was positively associated with SBP but
inversely associated with DBP (ESM Table 2).
Longitudinal associations between biomarkers
and hypertension
Among the biomarkers investigated, and in all GEE models
considered, sVCAM-1 was the only independent predictor of
both the prevalence and the incidence of hypertension
throughout the follow-up period (Table 4).
Reverse causality?
We also investigated the longitudinal associations between BP
or hypertension as determinants of subsequent (changes in)
levels of CRP, sICAM-1, sVCAM-1 and sE-selectin, but did
not find evidence to support a reverse causality hypothesis
(ESM Table 3).
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Fig. 2 Twenty-year time course of CRP (a), sICAM-1 (b), sVCAM-1
(c) and sE-selectin (d). Data show geometric means and 95% CIs, adjust-
ed for time-independent and time-dependent covariates; dashed lines rep-
resent unadjusted levels of biomarkers. The levels of biomarkers at dis-
ease onset (indicated by arrow) are shown for descriptive purposes only.
*p < 0.05, **p < 0.01 and ***p < 0.001 vs 0–2 years (baseline)
Table 2 Tracking of BP and biomarkers of inflammation and endo-
thelial dysfunction over the 20 years of follow-up
Variable Model 1a Model 2b
BP
SBP 0.40 (0.29, 0.51) 0.36 (0.26, 0.47)
DBP 0.32 (0.19, 0.46) 0.30 (0.17, 0.42)
MAP 0.39 (0.26, 0.52) 0.36 (0.23, 0.48)
Pulse pressure 0.28 (0.17, 0.39) 0.26 (0.15, 0.36)
Biomarkers
CRP 0.28 (0.18, 0.36) 0.26 (0.20, 0.33)
sICAM-1 0.60 (0.52, 0.67) 0.61 (0.57, 0.66)
sVCAM-1 0.58 (0.50, 0.66) 0.58 (0.53, 0.64)
sE-selectin 0.78 (0.71, 0.84) 0.79 (0.75, 0.82)
Data show 20 year tracking coefficients (95% CI); these are equivalent to
longitudinal correlation coefficients with values that can vary between 0
(no correlation) and 1 (perfect correlation)
aModel 1, adjusted for sex, age at onset of type 1 diabetes, smoking status
(time-independent covariates) and time
bModel 2, model 1 further adjusted for all other time-dependent covari-
ates (i.e. BMI, HbA1c, total cholesterol, serum creatinine, urinary AER,
insulin dose and MAP or biomarkers)
All tracking coefficients were significant at p < 0.001 level
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Table 3 Longitudinal associa-
tions between biomarkers of in-
flammation/endothelial dysfunc-
tion and pulse pressure
GEE model/main determinant Model 1a Model 2b Model 3c
Baseline
CRP −0.01 (−0.81, 0.80) −0.04 (−0.86, 0.78) −0.13 (−0.74, 0.49)
sICAM-1 3.22 (0.11, 6.33)* 3.19 (0.04, 6.35)* 2.97 (0.13, 5.80)*
sVCAM-1 3.76 (0.20, 7.33)* 3.84 (0.20, 7.49)* 1.76 (−1.33, 4.86)
sE-selectin 1.19 (−0.75, 3.13) 1.22 (−0.76, 3.21) 0.76 (−0.76, 2.27)
Time-lagged
CRP 0.75 (0.18, 1.33)* 0.27 (−0.32, 0.86) 0.26 (−0.28, 0.80)
sICAM-1 3.93 (0.62, 7.25)* 3.51 (0.24, 6.79)* 3.15 (0.44, 5.87)*
sVCAM-1 5.13 (1.86, 8.40)** 5.06 (1.86, 8.26)** 3.23 (0.49, 5.98)*
sE-selectin 0.95 (−0.70, 2.61) 0.99 (−0.71, 2.69) 0.92 (−0.43, 2.27)
Time-lagged (changes)
CRP 0.38 (−0.09, 0.85) 0.13 (−0.37, 0.63) 0.18 (−0.32, 0.67)
sICAM-1 2.04 (−0.23, 4.31) 2.09 (−0.28, 4.47) 2.47 (0.16, 4.78)*
sVCAM-1 3.36 (0.85, 5.86)** 3.53 (0.93, 6.12)** 2.54 (0.12, 4.96)*
sE-selectin 0.70 (−0.35, 1.76) 0.63 (−0.54, 1.81) 0.62 (−0.49, 1.73)
Data show longitudinal linear regression coefficients (95% CI), indicating difference (in baseline and time-lagged
models) or increase (changes model) in blood pressure (in mmHg) per doubling in biomarker (n = 277)
To re-express these association estimates per 10% increase in biomarker multiply by loge(1.1) = 0.095 or ~0.1
aModel 1, adjusted for sex, age at onset of type 1 diabetes, smoking status (time-independent covariates) and time
bModel 2, model 1 further adjusted for BMI, HbA1c, total cholesterol, serum creatinine, urinary AER and insulin
dose (time-dependent covariates, except in the baseline model where only their baseline levels were considered)
cModel 3, model 2 further adjusted for (changes in) MAP (time-dependent covariate)
*p < 0.05 and **p < 0.01
Table 4 Longitudinal associa-
tions between biomarkers of in-
flammation/endothelial dysfunc-
tion and hypertension
GEE model/main
determinant
Prevalence of hypertension (n = 277) Incidence of hypertension (n = 271)a
Model 1b Model 2c Model 1b Model 2c
Baselinea
CRP 1.12 (0.92, 1.36) 1.06 (0.87, 1.29) 1.14 (0.91, 1.42) 1.13 (0.90, 1.43)
sICAM-1 1.79 (0.78, 4.10) 1.77 (0.74, 4.25) 2.19 (0.87, 5.53) 2.26 (0.85, 5.80)
sVCAM-1 3.02 (1.25, 7.31)* 3.60 (1.36, 9.53)** 2.83 (1.10, 7.27)* 2.89 (1.08, 7.75)*
sE-selectin 1.65 (1.03, 2.65)* 1.44 (0.87, 2.38) 1.42 (0.85, 2.39) 1.37 (0.78, 2.39)
Time-lagged
CRP 1.13 (0.98, 1.30) 1.00 (0.88, 1.15) 1.23 (0.95, 1.59) 1.21 (0.92, 1.59)
sICAM-1 2.21 (1.06, 4.60)* 1.90 (0.91, 4.00) 2.73 (0.96, 7.76) 2.89 (0.93, 9.01)
sVCAM-1 2.40 (1.16, 4.94)* 2.28 (1.03, 5.25)* 3.00 (1.06, 8.54)* 3.06 (1.01, 9.26)*
sE-selectin 1.14 (0.74, 1.77) 1.18 (0.78, 1.77) 1.66 (0.94, 2.93) 1.53 (0.82, 2.83)
ORs (95% CIs) are shown for prevalence of hypertension or for incidence of hypertension per doubling in
biomarker
a Excludes three individuals with hypertension at baseline and three who died before the first follow-up
measurement
bModel 1, adjusted for sex, age at the onset of type 1 diabetes, smoking status (time-independent covariates) and
time;
cModel 2, model 1 further adjusted for BMI, HbA1c, total cholesterol, serum creatinine, urinary AER and insulin
dose (time-dependent covariates, except in the baseline model where only their baseline levels were considered);
*p < 0.05 and **p < 0.01
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Additional analyses
Given that CRP and BP were associated with each other but
seemingly not in a causal fashion, we examined an alternative
hypothesis: that both CRP and BP were, instead, determined
by (a) common factor(s). After adjustments for the time-
independent and time-dependent covariates, we found that
(changes in) BMI (per kg/m2) observed in the course of
follow-up (mean rate of increase 0.12 kg/m2 per year [95%
CI 0.10, 0.13], p < 0.001) was the single common determinant
of subsequent pulse pressure (0.58 mmHg [0.26, 0.89] in
time-lagged GEE model and 0.32 mmHg [0.09, 0.55] in
change GEE model), prevalence of hypertension (OR 1.22
[1.14, 1.33]), incidence of hypertension (OR 1.10 [1.00,
1.21]) and subsequent levels of CRP (5.0% [1.5, 8.5] in
time-lagged GEE model and 3.0% [0.1, 5.9] in time-lagged
changes GEE model).
Additional analyses of whether the associations reported
differed by age at onset, sex, (micro)albuminuria status or time
revealed no consistent effect modification by any of these
factors.
Discussion
We examined the longitudinal course of BP and biomarkers of
endothelial dysfunction and inflammation, and their inter-re-
lationships, in a cohort of individuals with type 1 diabetes who
had been followed for 20 years since the onset of disease. Our
main findings were as follows: (1) increases in levels of CRP,
sICAM-1 and sVCAM-1 occurred early in the course of dis-
ease and preceded the increases in BP; (2) all variables tracked
considerably over time, particularly sICAM-1, sVCAM-1 and
sE-selectin; (3) higher sICAM-1 and sVCAM-1, at baseline
and during follow-up, predicted the subsequent (changes in)
levels of pulse pressure; higher levels of sVCAM-1, at base-
line and during follow-up, predicted the prevalence and inci-
dence of hypertension; (4) notably, these associations were
independent of age, sex, smoking history and other relevant
risk factors and (5) we found no evidence for a reverse causa-
tion hypothesis (i.e. that higher levels of BP or hypertension
determined subsequent increases in these biomarkers). The
unique characteristics of this study were the repeated assess-
ment of biomarkers, BP and important covariates over the
natural course of disease during a period of 20 years. This
allowed us to examine, for the first time with a truly longitu-
dinal design, the temporal relationships between biomarkers
and BP (notably, pulse pressure) in individuals with type 1
diabetes. As such, the present study provides the strongest
evidence regarding the involvement (or lack thereof) of
CRP, sICAM-1, sVCAM-1 and sE-selectin in the pathogene-
sis of elevated pulse pressure and of hypertension, over the
course of disease in individuals with type 1 diabetes.
Tracking of BP and CRP levels over the 20 year follow-up
period was moderate but was very high for sICAM-1,
sVCAM-1 and sE-selectin. Interpretation of the tracking co-
efficients reported here requires consideration of a number of
factors [25]. First, these coefficients reflect only the stability of
one’s rank position vs peers over time. Second, the magnitude
of these coefficients tends to decrease with the length of fol-
low-up. Remarkably, the tracking coefficients of the BP vari-
ables were comparable with those reported in a 15 year longi-
tudinal study among healthy individuals followed from ado-
lescence to young adulthood [25]. To our knowledge, long-
term tracking coefficients for the biomarkers examined herein
have never been reported before. The very high tracking of
both CAMs suggests that they can be used to identify, early in
the disease, those who are likely to remain with adverse levels
leading to related sequelae. Third, measurement error attenu-
ates tracking coefficients, which may explain why these were
stronger for the biomarkers than for BP. Indeed, throughout
the years, BP was measured in the clinical setting as part of the
routine follow-up care provided to patients by different attend-
ing physicians and nurses, whereas biomarkers were all
assessed at the same laboratory at the same time, using the
same methodology. Finally, tracking coefficients may also be
affected by extraneous factors, although adjustments for both
time-independent and time-dependent covariates only seemed
to attenuate their magnitude slightly.
Epidemiological evidence to support the concept of arterial
stiffness/widened pulse pressure and hypertension as a conse-
quence of vascular/systemic inflammation has been controver-
sial [11, 26–29]. Our findings are in agreement with previous
studies showing that higher levels of CRP are related to hyper-
tension and pulse pressure [26, 30–35]. However, after life-
course adjustments for confounders, the associations with pulse
pressure and hypertension were markedly attenuated and no
longer significant, suggesting that these associations are not
causal. These findings are supported by previous studies show-
ing that the cross-sectional associations between CRP and hy-
pertension, as well as pulse pressure [27] or aortic pulse wave
velocity [29], disappeared after adjustment for life-course con-
founding or Mendelian randomisation tests of causality.
Furthermore, although some prospective studies have shown
associations between CRP and incident hypertension [36, 37],
others have shown these to disappear after adjustment for BMI
[38], suggesting that BMI is a common determinant of both
pulse pressure/hypertension and CRP [11]. Our data supports
this hypothesis. Increases in BMI and related BP in individuals
with type 1 diabetes have been well documented as long-term
consequences of intensified insulin treatment [39, 40]. In addi-
tion, increases in CRP, but not in CAMs, have been shown to
depend on the degree of weight gain in insulin-treated patients
with type 1 diabetes [41]. We [8, 42], and others [7], have also
shown that BMI is the strongest correlate of CRP in these
individuals.
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Our findings suggest that, in contrast to CRP (and
sE-selectin), both CAMs may causally underlie arterial stiffen-
ing. This contention holds inasmuch as arterial stiffness can be
depicted by pulse pressure and may be too strong given that
stroke volume (not measured) is also likely to explain a part of
the variance in pulse pressure, particularly among young indi-
viduals. Our findings also suggest that sVCAM-1 seems to
causally underlie the development of hypertension. This obser-
vation is in striking agreement with the only prospective study
thus far that has examined CAMs and pro-inflammatory cyto-
kines as predictors of incident hypertension among individuals
with type 1 diabetes [43]. Indeed, in that study only the baseline
levels of sVCAM-1 (but not sICAM-1, CRP, IL-6 and TNF-α)
were associated with the 15 year cumulative incidence of
hypertension. We extended these observations by examining
not only associations with levels of biomarkers at baseline but
also their changes during follow-up. Soluble CAMs are
markers of vascular endothelial dysfunction/inflammation that
may influence functional stiffening of large arteries through
reduced availability of nitric oxide and/or increased activity
of vasoconstrictors such as endothelin-1, both of which affect
vascular smooth muscle cell tone [9]. In addition, endothelial
dysfunction/inflammation may lead to smooth muscle cell pro-
liferation and increased synthesis of structural proteins such as
collagen within the vascular wall, leading to structural stiffen-
ing of large arteries [3, 9]. Previous studies on soluble CAMs
and BP have produced contradictory findings but have been
mostly cross-sectional and not focused on the pulsatile compo-
nent of BP [44–50]. Appreciation of the BP curve as a summa-
tion of a steady component (MAP) and a pulsatile component
(pulse pressure) has provided additional information in terms of
CVD risk prediction to that traditionally obtained on the basis
of elevated SBP and/or DBP alone [5].
We used brachial, not central, pulse pressure as a crude
estimate of arterial stiffness, reflecting the data that was acces-
sible from clinical records. The technology enabling non-
invasive measurement of central pulse pressure and aortic
pulse wave velocity, that would allow better characterisation
of the aetiology of arterial stiffening, was not available during
the 20 year period covered by the present study. Nevertheless,
brachial pulse pressure still provides valuable risk prediction
information: in ameta-analysis (not including individuals with
type 1 diabetes), central pulse pressure tended to be more
strongly associated with incident CVD and mortality than bra-
chial pulse pressure but the added value of central pulse pres-
sure in risk prediction was only marginal [51]; a similar pat-
tern was observed in a large cohort study of individuals with
type 1 diabetes [4].
There are some additional limitations to our study. Findings
were confined to individuals with type 1 diabetes and there-
fore may not generalise to the background population.
Measurement errors around BP measurements are likely to
have led to an underestimation of the associations estimates
reported in the present manuscript. We only measured CRP,
sICAM-1, sVCAM-1 and sE-selectin, which reflect just a part
of the complex and multifaceted process of arterial remodel-
ling induced by endothelial dysfunction and inflammation [9].
Still, although the CAMs studied here may be produced by
different cell types, changes in their plasma levels are widely
considered to reflect altered endothelial production rates [9].
The biomarkers were measured on stored blood samples,
which raises the question of whether the reported increases
in their levels over time could in part reflect a decay of the
proteins with storage time. We deem this unlikely because of
the high long-term stability of concentrations of these proteins
in stored serum [52]. Besides, while levels of CRP, sICAM-1
and sVCAM-1 increased, levels of sE-selectin decreased over
time. In addition, despite the long storage time, our measure-
ments could capture considerably higher levels of biomarkers
at disease onset (excluded from the analyses) followed by
decreases after blood-glucose stabilisation, with relatively
steady increases (except for sE-selectin) thereafter (see Fig. 2).
In conclusion, in individuals with type 1 diabetes, increases
in sICAM-1 and sVCAM-1 precede, and are associated with,
subsequent increases in pulse pressure and hypertension
throughout the course of the disease, supporting the involve-
ment of endothelial dysfunction/inflammation in the develop-
ment of premature arterial stiffening. The lack of support for a
causal link between CRP and BP, and the observation that
both derive from a common antecedent (BMI), suggests that
weight gain should be monitored during treatment of individ-
uals with type 1 diabetes. Targeting endothelial dysfunction/
inflammation in the early stages of diabetes may slow down
the accelerated arterial ageing characteristic of this disease and
prevent related cardiovascular sequelae. Given that both
CAMs tracked very highly, measuring their levels and chang-
es soon after the onset of type 1 diabetes may enable identifi-
cation of individuals at a high risk and who may need
intensified/tailored treatment.
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